Abstract:Several patients do not benefit from anti-cancer immunotherapies due to resistance for metabolic adaptation and fitness of tumor cells. Highly glycolytic tumor cells outcompete effector T cells for glucose in the tumor microenvironment (TME), impairing T cell function. High levels of lactate dehydrogenase (LDH) correlate with poor prognosis in cancer patients undergoing immunotherapies, inducing aberrant angiogenesis by activating HIF-1α and VEGF expression in endothelial cells (ECs), underscoring a biological interplay between tumor metabolism and neo-angiogenesis that can impact anti-tumor immunity. Main vasculature cells – ECs and pericytes (PCs) – may serve as antigen-presenting cells (APC), influencing T cell responses. While these findings point to a joint metabolic and immune regulation of the vasculature:T-cell crosstalk in the TME, we currently lack a precise understanding of the mechanisms linking tumor metabolism, aberrant angiogenesis, and anti-tumor T-cell responses, and how cell-based therapy may be influence by these factors. We have compared and contrasted vasculature and immune cells phenotypes by high-dimensional flow cytometry in established tumor models representing three major metabolic states by perturbing the two main cellular hubs for producing energy (aerobic glycolysis, by LDHA knock-down; oxidative phosphorylation, by depleting mitochondria as in Rho0 cells) compared to control tumors (NC). We functionally tested the impact of intratumor T cell recruitment according to these phenotypes, by adoptive cell transfer (ACT) therapy using T cells from donor mice immunized with matched-tumor injected i.v. in RAG2 KO mice bearing metabolically-defective tumor (KD or Rho0) and control tumor (NC) in contralateral mammary fat pad. We found that glycolysis-low tumors (LDH-A KD) show a better vasculature with reduced proportions of angiogenic activated PCs (cluster1: NG2+PDGFRbneg) and increased frequencies of "stabilizing" PCs (cluster 2: NG2negPDGFRb+, which counteract the formation of leaky vessels), compared to NC. However, KD tumors also display a reduction in MECA-79+ high endothelial venules. Moreover, LDHA-KD vs. NC tumors displayed ECs and cluster 2 PCs with greater expression of MHCI and decreased expression of FAS-L, and more EC expressing MHCII or PD-L1. In addition, the immune infiltrate of KD tumors is characterized by increased amounts of T effector cells and lower amounts of Gr1-low myeloid derived suppressor cells (MDSCs). The changes in vascularization phenotype have been confirmed in RAG2 KO mice bearing bilateral tumor variants model. ACT in these mice bearing bilateral 4T1-NC and -KD tumors resulted in greater biodistribution of T cells in the KD tumors, showing decreasing tumor growth. Vasculature features correspond to greater intratumor T-cell trafficking, indicating a mechanistic link between tumor glycolysis, aberrant angiogenesis, and T-cell exclusion. This would aim to elucidate the mechanisms through which these processes are connected for developing more efficacious T-cell-targeted therapies. Citation Format: Giorgia Colombo, Jee Hye Kang, Inna Serganova, Roberta Zappasodi. Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B049.

Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors

Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1

Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

Antitumor Effect of a Whole Tumor Cell Vaccine Expressing Human Fibroblast Activation Protein in Murine Tumor Models.

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Effect of FAPα-expressing tumor cell vaccine with PD-1 mAb on its efficacy in mice colorectal cancer model.

663 Media based on the metabolic composition of tumor interstitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite phosphoethanolamine

Abstract B025: A T cell engager targeting cancer associated fibroblasts inhibits tumor growth and modulates the tumor microenvironment

Abstract 716: Depletion of stromal cells remodels tumor microenvironment and potentiates immune checkpoint blockade in pancreatic cancer

Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity

Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy

Combination Therapy of HIFα Inhibitors and Treg Depletion Strengthen the Anti‐tumor Immunity in Mice

Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein

Abstract C036: Restoration of T effector cells function by targeting senescent cancer-associated fibroblast in tumor microenvironment of stroma-rich cancers

Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment

Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy

Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model

Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.